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Characterization and structural 
determination of a new anti-MET 
function-blocking antibody with 
binding epitope distinct from the 
ligand binding domain
Danielle M. DiCara1,2,10, Dimitri Y. Chirgadze3, Anthony R. Pope4, Aneesh Karatt-Vellatt4, Anja 
Winter  3,11, Peter Slavny4, Joop van den Heuvel  5, Kothai Parthiban4, Jane Holland6, Len 
C. Packman3, Georgia Mavria7, Jens Hoffmann8, Walter Birchmeier6, Ermanno Gherardi1,2,9 & 
John McCafferty3,4
The growth and motility factor Hepatocyte Growth Factor/Scatter Factor (HGF/SF) and its receptor, the 
product of the MET proto-oncogene, promote invasion and metastasis of tumor cells and have been 
considered potential targets for cancer therapy. We generated a new Met-blocking antibody which 
binds outside the ligand-binding site, and determined the crystal structure of the Fab in complex with 
its target, which identifies the binding site as the Met Ig1 domain. The antibody, 107_A07, inhibited 
HGF/SF-induced cell migration and proliferation in vitro and inhibited growth of tumor xenografts 
in vivo. In biochemical assays, 107_A07 competes with both HGF/SF and its truncated splice variant 
NK1 for MET binding, despite the location of the antibody epitope on a domain (Ig1) not reported 
to bind NK1 or HGF/SF. Overlay of the Fab-MET crystal structure with the InternalinB-MET crystal 
structure shows that the 107_A07 Fab comes into close proximity with the HGF/SF-binding SEMA 
domain when MET is in the “compact”, InternalinB-bound conformation, but not when MET is in the 
“open” conformation. These findings provide further support for the importance of the “compact” 
conformation of the MET extracellular domain, and the relevance of this conformation to HGF/SF 
binding and signaling.
A major challenge in the therapy of solid tumors, and notably of carcinomas that constitute over 85% of all human 
cancers, is the development of agents that inhibit metastasis, namely the growth of cells derived from the primary 
tumor at distant sites in the body. Metastasis is a multi-stage process in which cancer cells migrate into adjacent 
tissues (invasion), cross the wall of blood or lymphatic capillaries to be transported across the general circulation 
(intravasation), exit from the bloodstream into a secondary tissue/organ (extravasation) and finally give rise to 
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secondary tumors1. In principle, each of these stages may be targeted in therapy, and the ability to target multiple 
stages simultaneously is an attractive prospect.
The signaling system mediated by the growth and motility factor HGF/SF and its receptor MET, the tyros-
ine kinase encoded by the MET proto-oncogene, has multiple and essential physiological roles in vertebrate 
embryogenesis, where it is required for normal development of the liver parenchyma and the labyrinth layer 
of the placenta2, 3 as well as distant migration of the myogenic precursor cells4. HGF/SF and MET have further 
and important physiological roles in postnatal life, where they control the regeneration after injury of several 
epithelial organs including skin5 and liver6, 7. They also exert, however, multiple and crucial roles in the early 
stages of metastasis of epithelial cancers by controlling (i) delamination of epithelial cells and the process of 
epithelial-mesenchymal transition crucial for long distance epithelial cell migration4, 8, (ii) degradation of the 
basement membrane and remodeling of the extracellular matrix via urokinase9 and matrix metalloproteinases10, 
(iii) integrin-dependent migration of cancer cells as a result of activation of focal adhesion kinase and paxillin11, 
(iv) formation of the pre-metastatic niche via tumor-derived exosomes12, (v) tumor lymphangiogenesis13, 14, a 
process essential for lymphatic metastasis and, (vi) haemangiogenesis15, 16. Further, there is growing evidence for 
a major role of HGF/SF and MET in the maintenance of cancer stem cells in colon17, breast18 and prostate19 car-
cinomas, and accumulating reports of involvement of the MET-HGF/SF axis in cancer cell resistance to targeted 
therapies both in vitro20–23 and in cancer patients24–26.
The MET receptor is a single-pass transmembrane protein consisting of a large extracellular ectodomain, a 
transmembrane segment and an intracellular receptor tyrosine kinase domain27. The ectodomain is a heterodimer 
arising from furin cleavage of a single precursor chain and consists of an N-terminal 283 amino acid α-chain and 
the 625 extracellular amino acids of the β-chain. An N-terminal semaphorin homology domain (SEMA), which 
binds the ligand HGF/SF, is followed by a “stalk” comprising one cysteine rich (CR) domain and 4 immunoglobu-
lin domains termed Ig1-Ig428. The MET ectodomain has been expressed recombinantly as a series of truncations 
containing the SEMA, CR and 0, 2 or 4 Ig domains, which we will refer to as MET567, MET741 and MET928, 
respectively. HGF/SF consists of an amino terminal domain, 4 kringle domains (K1 - K4) and a C terminal serine 
protease homology domain (SPH domain). The N terminal and first kringle domain (NK1) of the HGF/SF ligand 
drive a high affinity interaction with MET29, and the SPH domain also binds MET30. The SEMA domain has been 
reported as necessary and sufficient for HGF/SF binding28, although an interaction with the Ig3-Ig4 “lower stalk” 
region has also been reported31.
Here, we report the isolation of a new human, phage-derived monoclonal antibody to MET (107_A07) dis-
playing potent receptor antagonistic activity, and we describe the activity of 107_A07 on cancer cells in vitro 
and in in vivo. We also report a crystal structure of the 107_A07 Fab in complex with a MET receptor fragment 
containing amino acids 519–740, which includes the CR, Ig1 and Ig2 domains but not the ligand-binding SEMA 
domain. These data provide insights into the conformation of MET during ligand binding and cell signaling.
Materials and Methods
Protein production and purification. Soluble MET741 protein28 was produced from CHO Lec3.2.8.1 
cells and purified by affinity chromatography (NiNTA Superflow, Qiagen) followed by cation exchange (MonoS, 
GE Life Sciences). 107_A07 and D1.3 Fabs and IgG –formatted antibodies were produced by transfection of 
suspension HEK293F cells (Invitrogen) with Valproic Acid (Sigma) added to 4 mM following transfection. Fab 
proteins were purified using affinity resins KappaSelect and/or GammaBind Plus (GE Life Sciences). IgG for-
matted antibodies were purified by Protein A affinity chromatography. For cell cycle analysis, 107_A07 and D1.3 
Fabs were further purified by gel filtration chromatography (Superdex 200 10/300 (GE Life Sciences). Unless 
stated otherwise, 7A2 scFv was produced in Pichia pastoris and purified by Ni-NTA chromatography followed 
by gel filtration. Anti-MET antibody 5D5 sequences were obtained from US Patent No. 7,476,724 B2. Heavy and 
light chains were synthesized (GeneArt, Thermo Fisher Scientific) with restriction sites that allowed cloning into 
Fab vectors pBIOCAM1-3F and pBIOCAM3-3F, expressed in HEK293F cells and the Fab purified by Ni-NTA 
chromatography.
FAb PEGylation. Recombinant Fab were partially reduced with TCEP and PEGylated with 
maleimide-activated PEG (Sunbright ME-200 MAOB or Sunbright ME-200MA3, NOF Europe). PEG-Fab and 
free PEG were monitored by SDS-PAGE and barium chloride & iodine staining32.
Isolation & affinity maturation of functional MET-blocking antibodies by phage dis-
play. Biopanning with a scFv phage library33 was performed on solid-phase recombinant MET928 and light 
chain shuffling performed on the output by cloning the resulting VH gene pool back into the original scFv phage 
library34. Biopanning with the chain-shuffled library (109 clones) was performed with biotinylated MET928 in 
solution and streptavidin-coated dynabeads. Phage pools were cloned into expression vector35 and small-scale 
expressions performed in BL21 (DE3) bacteria in 96-well format. Approximately 960 supernatants were screened 
directly for inhibition of HGF/SF-induced scatter of BxPC-3 human pancreatic cancer cells. Affinity matura-
tion was performed by diversification of the CDR3 regions of 7A2 VH and VL using oligonucleotide-directed 
mutagenesis and stringent selection of the resulting phage library with biotinylated MET928 in solution.
In vitro cell-based assays. HGF/SF-induced cell migration across a porous membrane coated with 100 µg/
ml collagen (Purecol, Nutacon) was analyzed using a modified Boyden chamber assay. Cells (SKOV-3 or U87MG) 
were labeled with the fluorescent dye Calcein AM (Life Technologies) and migration assessed by quantification of 
fluorescence on the underside of the membrane using a Typhoon instrument (GE Life Sciences). Data were ana-
lysed with ImageQuant software and background fluorescence subtracted. For cell cycle analysis, U87MG human 
glioblastoma cells were serum-starved for 48 hours prior to a 24 hour incubation with 300 pM HGF/SF with or 
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without 0.9 µM 107_A07 FAb or 1 µM D1.3 FAb. Cells were trypsinised, fixed, stained with propidium iodide in 
the presence of RNAse and analyzed by flow cytometry according to standard procedures. In vitro angiogenesis 
assay was performed using the modified co-culture assay as described previously36. Briefly, fibroblast cells were 
seeded in gelatin-coated chamber slides. Human umbilical vein endothelial cells (HUVECs) were seeded on to 
the confluent fibroblasts and D1.3 and 107_A07 antibodies (200 nM) were added to the cells. The co-cultures were 
fixed and stained for CD31. Number of tubules was counted manually from 10 fields for each well and the field 
area was measured using AngioSys 1.0 imaging software.
Tumor xenografts. NMRI nu/nu mice (Crl:NMRI-Foxn1nu) were obtained from Charles River Laboratories 
(Sulzfeld, Germany). U87MG cells were obtained from ECACC and identity checked at the DSMZ. Mice were 
injected subcutaneously with 107 U87MG human glioblastoma cells and antibody administered every 3–5 days 
between day 7 and 33, when treatment stopped. Groups of 8 mice were treated with 107_A07 IgG at either 2 mg/
kg or 10 mg/kg. Control animals were treated with either PBS or D1.3 IgG at 10 mg/kg. All animal experiments 
were carried out in accordance with the United Kingdom coordinating committee on cancer research regulations 
for the welfare of animals and the German Animal Protection Law, and were also approved by the local responsi-
ble authorities Landesamt für Gesundheit und Soziales Berlin (LAGeSo).
Surface Plasmon Resonance (SPR) studies. KD was determined using a Biacore instrument and 
represents the mean of three experiments using 107_A07 FAb purified sequentially on both KappaSelect and 
GammaBind Plus chromatographic resins. For competition analysis by SPR, a CM5 chip coated with MET928 
was exposed to: 7A2 scFv (134 nM, 268 nM), NK1 (238 nM, 476 nM) or a mixture of the two (134 nM 7A2 scFv, 
238 nM NK1).
Competition analysis by ELISA. Fabs were mixed with 100 nM MET928 one hour before addition to 
microplates coated with HGF/SF or the fragment NK1. After one hour bound MET928 was detected with anti-
5xHis (Qiagen) followed by DELFIA® Eu-N1 rabbit anti-mouse-IgG. DELFIA® enhancement solution was then 
added and signal quantitated using time-resolved fluorescence with a Fusion instrument (Perkin Elmer).
Complex formation analysis. Fab and MET proteins were co-incubated at a 3:2 molar ratio for 140 min-
utes at room temperature in 25 mM Tris pH 7.4, 150 mM NaCl, centrifuged and analyzed by size exclusion chro-
matography (Superdex 200 10/300).
Co-crystallization of MET/Fab complex. Briefly, Fab 107_A07 and his-tagged MET741 were 
co-incubated, then digested with Pepsin and EndoHf deglycosidase. The remaining complex was purified by 
Ni-NTA affinity resin and size exclusion chromatography, concentrated to 5.9 mg/ml and crystallized by the 
sitting-drop vapor diffusion method at 19 °C.
Data collection & model generation. X-ray data collection experiments were performed at the European 
Synchrotron Radiation Facility (Grenoble France), beamline ID29. The crystals diffracted to a maximum resolu-
tion of 2.6 Å. The crystals contained two molecules of the MET/Fab complex in the asymmetric unit. The crystal 
structure was solved using the Molecular Replacement (MR) method. After several rounds of manual rebuilding 
and refinement the R/Rfree values reached 21.5% and 25.7% respectively. The coordinates of the structure have 
been deposited to the Protein Data Bank under accession ID 5LSP. Additional method information is provided in 
the Supplementary Information file.
Additional Disclosures. D.D.C., A.P., J.M.C. and E.G. are co-inventors on a patent application relating to 
the antibodies described in this manuscript. D.D.C. is currently an employee of Genentech, Inc.
Results
Generation and affinity maturation of a high affinity antibody blocking MET signal-
ing. Recombinant antibodies recognizing MET928 were generated by phage display using two rounds of pan-
ning on immobilized antigen. Binders were generated using a previously described human antibody phage display 
library of ~1010 clones formatted as single chain Fvs (scFvs)33. The selected population was affinity matured en 
masse by chain-shuffling the selected population of VH genes34. A chain-shuffled scFv library of 109 clones was 
constructed and was subjected to stringent selection using biotinylated MET928 to allow the emergence of new 
VH/VL combinations with potentially superior binding properties to the original. In addition to affinity-based 
approaches, a “competitive elution” selection was performed in parallel in which MET-bound phage popula-
tions were incubated with high (micromolar) concentrations of the ligand HGF/SF in an effort to elute HGF/
SF-competitive antibodies. Selected populations were cloned into a bacterial expression vector35 and individual 
clones were screened directly for functional activity using a colony scatter assay. Hits emerging from this screen 
were assessed in a more quantitative cell migration assay, based on migration of fluorescently labeled SKOV3 
human ovarian cancer cells using a Boyden chamber. A number of clones were identified that inhibited HGF/
SF-induced migration of SKOV3 cells, including clone 7A2 (Supplementary Figure S1) which emerged from 
“competitive elution” selections. This clone was antagonistic for ligand-induced MET activation but also exhibited 
a degree of agonism when tested in the absence of added ligand. Specifically, a “bell-shaped” curve, similar to that 
seen with the natural ligand, was observed with peak agonistic activity around 1 nM 7A2 scFv and a maximum 
peak height which was lower than that induced by HGF/SF (Fig. S1). It has previously been shown that anti-Met 
antibodies presented in a bivalent format can display agonistic activity37. It is also known that scFv molecules can 
form dimers and other higher order structures. Separation of monomeric scFv from larger species revealed that 
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agonistic activity in scFv preparations was associated with larger, non-monomeric species (data not shown). Fab 
are much less likely than scFv to form higher-order species, and so we converted 7A2 to a Fab format.
Conversion of 7A2 to a Fab format diminished the agonistic activity as expected but also resulted in reduced 
affinity and potency, therefore an additional round of affinity maturation was conducted using oligonucleotide 
directed mutagenesis to create phage display libraries where the CDR3 region of the V gene heavy chain (VH) was 
diversified. Mutagenic primers with contiguous blocks of 5–6 randomized amino acids using 3 overlapping prim-
ers were used to randomize the 11 amino acids of the VH CDR3 and 9 amino acids from VL CDR3. Stringent 
selections were carried out using limiting amounts of biotinylated MET928 down to 10 pM. DNA from the output 
of the resulting selections was subcloned into a bacterial expression vector and 1152 clones were screened by 
ELISA and sequenced. 146 clones with unique sequences that were positive in ELISA were identified for further 
study. VL mutants were not identified, suggesting this library was ineffective or was dominated by the parental 
sequence. The selected clones were expressed, purified and the off-rates compared to the parental 7A2 clone using 
surface plasmon resonance (SPR). The top 8 clones showing the greatest improvement in off-rate were identified 
and produced as Fab fragments. Sequence analysis revealed that the top group of clones came from VH CDR3 
mutagenesis and all carried a Y105W mutation. In addition, 6/8 of these clones retained G106 and M107 despite 
the complete diversification within this region of the selected clones. Based on affinity and potency rankings, the 
affinity-matured clone 107_A07 was selected for further biological and biochemical analysis. SPR experiments 
yielded a KD in the nanomolar range (3.2 ± 0.7 nM; mean ± SD, three experiments).
Antibody 107_A07 inhibits migration and proliferation of cancer cells and endothelial tubu-
logenesis. HGF/SF-mediated activation of MET causes cell proliferation, cell migration, and angiogene-
sis, all of which contribute to cancer progression38. We assessed 107_A07 Fab for inhibition of these processes. 
Inhibition of cell migration was compared with 7A2, the parental antibody of 107_A07, and as a control we also 
included a Fab-formatted version of 5D5.v1, the monoclonal antibody from which onartuzumab was derived37. 
107_A07 Fab dose-dependently inhibited HGF/SF-induced cell migration of SKOV-3 human ovarian cancer cells 
(Fig. 1A) and U87MG human glioblastoma cells (Fig. 1B).
A degree of agonism observed at higher concentrations with Fab formatted 107_A07 was lost following puri-
fication of monomers by size exclusion chromatography, suggesting that the presence of low concentrations of 
multimeric material could drive agonism (Figure S2). To assess antibody activity on HGF/SF-induced cell pro-
liferation, Fab were further purified by size exclusion chromatography and serum-starved U87MG cells were 
incubated for 24 hours with HGF/SF in the presence of 107_A07 Fab or a control Fab (humanized anti-hen egg 
lysozyme, D1.339), followed by DNA content analysis by propidium iodide staining. U87MG cells express HGF/
SF40 and divide rapidly in culture, however addition of exogenous HGF/SF caused a further and measurable 
increase in DNA synthesis (Fig. 1C). Treatment with 107_A07 Fab but not control (D1.3) Fab reduced the per-
centage of cells in S-phase and G2/M phase to basal levels, with a corresponding increase in cells in G1 (Fig. 1C).
We also investigated PEGylation of the 107_A07 Fab, since PEGylation can be used to extend Fab pharma-
cokinetics in vivo. PEGylation of 107_A07 Fab was achieved by covalent attachment of 20 kD polyethylene glycol 
(PEG) chains to the C-terminal cysteine residues41. The majority of unconjugated PEG was removed by size exclu-
sion chromatography and ultrafiltration. In SDS-PAGE, PEG-107_A07 Fab chains displayed reduced migration 
and insensitivity to reducing agents, consistent with removal of the inter-chain disulphide bond (Fig. S3). PEG-
107_A07 Fab retained the ability to inhibit HGF/SF-induced cell migration and demonstrated essentially com-
plete inhibition of cell migration at high concentrations (Fig. S4). In a fibroblast/endothelial cell in vitro model of 
angiogenesis in which fibroblast-derived HGF/SF induces human umbilical vein endothelial cell (HUVEC) tub-
ulogenesis (a process that recapitulates in vitro the sprouting of new capillaries in vivo) (Fig. 1D), PEG-107_A07 
Fab inhibited tubule formation (Fig. 1F and G).
107_A07 IgG inhibits the growth of human tumor xenografts in vivo. The VH and VL domains of 
107_A07 were expressed as an intact human IgG and the activity of 107_A07 IgG and control (D1.3) IgG were 
assessed in cell migration assays where agonism was found with 107_A07 IgG (Fig. S5). The peak of agonistic 
activity was again found to occur at low nanomolar concentration (as with the scFv, Fig. S1) with net antagonism 
found at higher concentrations (Fig. S5). 107_A07 IgG was administered over 26 days in a human U87MG glio-
blastoma cell xenograft model and inhibited tumor growth very effectively for up to 70 days at 10 mg/kg 107_A07 
IgG (Fig. 2). Thus intact 107_A07 IgG inhibited tumor growth despite its bivalent format (Fig. 2), presumably 
because an IgG concentration was maintained where net antagonism was achieved.
7A2/107_A07 binds within the Ig1-Ig2 domains of MET and competes with HGF/SF in biochem-
ical assays. Initial insights into the 7A2/107_A07 epitope and inhibitory mechanism were obtained by phys-
icochemical studies. 7A2 Fab was incubated with three soluble fragments of the MET ectodomain: MET567, a 
fragment comprising the SEMA and cysteine-rich (CR) domain, MET741 containing the SEMA, CR and Ig1-2 
domains and MET928 containing the SEMA, CR and Ig1-4 domains28. Complex formation was assessed by 
size exclusion chromatography and was readily detectable with constructs MET741 and MET928 but not with 
MET567 (Fig. 3A–C), indicating that the 7A2/107_A07 epitope is contained within the first two Ig-like domains 
of the MET stalk structure28, 42. Similar results were observed with 107_A07 Fab (not shown). In contrast, a 
Fab-formatted version of the anti-Met antibody 5D5 was found to bind all 3 fragments (not shown), consistent 
with binding to a distinct site within the ligand binding SEMA domain37. We next investigated whether 7A2/107_
A07 competes with HGF/SF or fragments of HGF/SF for binding to MET using SPR. Due to the rapid binding 
kinetics observed for 7A2, we compared binding of 7A2 and NK1 to immobilized MET extracellular domain 
(MET928) individually and when mixed. Clear competition for binding was observed with the mixture of 7A2 
and NK1 (Fig. 3D). Biochemical competition between 7A2 and NK1 was confirmed by solid phase assays in 
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Figure 1. 107_A07 FAb inhibits HGF/SF-induced cancer cell migration, DNA synthesis and angiogenesis in 
vitro. Effect of parental Fab-formatted 7A2 and matured 107_A07 Fab on SKOV3 (A) and U87MG (B) cell 
migration in the presence and absense of HGF/SF in a modified Boyden chamber assay. A Fab-formatted 
version of the anti-MET antibody 5D5 was used as a control. Closed and open symbols show respectively 
the effect of antibody in the presence and absence of HGF/SF. Data represent mean ± standard deviation of 
triplicate wells. (C) Cell cycle analysis by propidium iodide staining of fixed, serum-starved U87MG cells 
24 hours after exposure to 300 pM HGF/SF and/or Fab as indicated. Mean and standard deviation of (n) 
experiments are shown. (D,E,F and G) PEGylated 107A07 blocks angiogenesis in an in vitro angiogenesis assay 
in which co-culture with fibroblasts promotes endothelial cell sprouting and tubulogenesis. (D) control culture, 
no Fab, (E) PEG-D1.3 Fab, (F) PEG-107_A07 Fab, (G) quantification of endothelial tubules three days after the 
addition of Fab.
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which pre-incubation of MET928 with either 7A2 or 107_A07 inhibited MET binding to both HGF/SF and NK1 
(Fig. 3E and F).
Crystal structure of the 107_A07 and MET-107_A07 complex. In order to define further the epitope 
and inhibitory mechanism of these antibodies, we determined the crystal structure of a complex formed by the 
107_A07 Fab and a fragment of the MET ectodomain encompassing the small cysteine-rich domain and the 
upper stalk region (Ig domains 1 and 2). Initial crystallization experiments with complexes formed by the 107_
A07 Fab and MET741 failed to yield diffraction grade crystals. We overcame this by exploiting a pepsin cleavage 
site (NGL|GCR) located in the linker connecting the SEMA and CR domains of MET, generating a receptor 
fragment containing the CR, Ig1 and Ig2 domains of MET, which contains MET residues 519–741. Crystals of 
the 107_A07 Fab – MET519–741 complex were obtained and diffracted to a maximum resolution of 2.6 Å at the 
European Synchrotron Radiation Facility (Beamline ID29, ESRF, Grenoble, France). The structure was solved 
by the Molecular Replacement method43 and refined to Rcryst and Rfree values of 21.5% and 25.7% respectively 
(Table 1). The asymmetric unit contained two 107_A07 - MET519–741 complexes (Fig. 4A) that, when superposed 
on their MET-Ig1 domains, showed close alignment of the MET chain and VH and VL domains but approxi-
mately 60° rotation of the CH1 and CL domains. Complex 1, containing MET chain A and Fab chains H and L 
(Fig. 5A) is described below because the antibody-receptor interactions seen within this complex are more com-
plete than the ones seen in complex 2. The model contains MET residues 519–740. We also observed unexpected 
electron density adjacent to Cys584 in the Ig1 domain (Fig. 4B). MALDI analysis of the crystallization complex 
and subsequent MS/MS analysis identified a peptide containing amino terminal residues of MET (residues 22–32, 
which include a single cysteine at position 26) attached to the complex by a disulphide bond. Together, these data 
indicate the presence of a disulphide bond between MET residues Cys26 and Cys584. Since MET519–741 was puri-
fied by enzymatic digestion of the MET741–107_A07 complex, it is uncertain whether the attachment occurred 
before or after digestion.
The VH and VL domains of 107_A07 bind the Ig1 domain of MET (Fig. 5B) and bury 555 Å2 and 243 Å2 
respectively. The VH domain binds a discontinuous epitope including the tip of the β-hairpin (R592, N593 and 
K595), residues connecting the β-hairpin and the β-strand C (K599 and K600) and the tip of β-strand C (R602) 
(Fig. 5B and Supplementary Table S1) and involves an extensive network of polar contacts and salt bridges involv-
ing CDRs 1, 2 and 3 of the antibody heavy chain (Fig. 5C and Table S1).
The interactions of the VH domain with MET clarify the impact of the Y105W mutation that was found in 
each of the top 8 affinity matured clones. From the structure it is clear that the indole group of tryptophan creates 
an additional sidewall for the pocket formed by residues 99–105 of the heavy chain. This makes the pocket deeper 
and more complementary for the interactions with the antigen’s residue K599. The side chain of K599 is fully 
extended and inserts deep into the pocket, where the NH2 group creates an extensive hydrogen bonding network 
with the carbonyl groups of the backbone (Fig. S6). In contrast, the VL domain binds a linear epitope (L612, T613, 
L614, S615 and E616, a sequence corresponding to β-strand D of canonical E set domains) and makes limited 
contacts with MET predominantly via L3 (Fig. 5C and Table S1).
Within the 107_A07 Fab - MET complex, the conformation of the CR domain of MET relative to the Ig1-Ig2 
fragment matches closely the conformation of the corresponding region of MET observed in the crystal structure 
of MET741 in complex with InlB321. InlB321 is a truncated fragment of InternalinB (InlB), a surface protein of 
Listeria monocytogenes that promotes binding and internalization of the bacterium through binding and acti-
vation of the MET receptor44, 45 (PDB entry 2UZY). InlB321 binds with high affinity to a primary site in the Ig1 
domain of MET with its leucine-rich repeat central domain. It also binds with lower affinity to a secondary site 
in the SEMA domain with its interdomain repeat. Binding to both sites is essential for receptor activation44, 45.
In contrast to InlB321, 107_A07 appears to contact only the MET Ig1 domain; however, the C-alpha atoms 
for the CR-Ig1-Ig2 structure of the InlB-MET741 superpose closely with the corresponding MET domains in the 
107_A07 structure (r.m.s.d. is ~1.4 Å from the MET molecule in complex 1 and ~2.0 Å for the MET molecule in 
Figure 2. Effect of 107_A07 IgG on the growth of subcutaneous U87MG xenografts. Following xenograft 
implantation on day 0, mice (n = 8) were given vehicle alone (PBS), control D1.3 IgG (10 mg/kg) or 107_A07 
IgG (2 or 10 mg/kg) intraperitoneally at day 7 and then every 3–5 days for 26 days. Tumor volumes were 
measured by caliper twice weekly.
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complex 2 (Fig. 5D). Although extensive movements of the SEMA domain relative to the CR domain are enabled 
by the SEMA-CR domain linker30, 37, 44, 45, the structure of the MET CR-Ig1-Ig2 section reported here is rigid, due 
to extensive interactions between the top of Ig1 (notably the β-hairpin structure) and the CR domain (Fig. 5E), in 
addition to a second set of interactions between Ig1 and Ig2 (Fig. 5F).
Discussion
We have isolated and affinity matured a novel phage-derived anti-MET antibody, 7A2/107_A07, which competes 
for binding with both MET ligand HGF/SF and the HGF/SF fragment NK1. Antibody 7A2/107_A07 inhibited 
HGF/SF-induced cell migration and DNA synthesis in vitro, endothelial cell tubulogenesis in a co-culture assay 
and tumor growth in vivo in a xenograft model. Biochemical analysis and structural determination demonstrated 
that the antibody binds to the Ig1 domain, in contrast to HGF/SF, which binds to the SEMA domain.
Figure 3. 7A2 and 107_A07 bind within the Ig1-Ig2 domains of MET and compete with NK1 for MET binding. 
Panels A–F show size exclusion chromatography analysis of 6 µM Fab 7A2 (A–C) or 107_A07 (D–F) and 4 µM 
MET567 (A,D), MET741 (B,E) or MET928 (C,F), alone or following co-incubation. Y-axis indicates absorbance 
at 280 nm and x-axis elution volume. Dark blue line, MET alone; gray line, Fab alone; red line, MET/Fab 
mixture. Peaks present only in MET-Fab mixtures represent complex formation and are marked with an asterix. 
(G) Binding to a MET928-coated CM5 Biacore chip of 7A2 scFv (light gray line, 134 nM), NK1 (light blue line, 
238 nM), or 7A2 scFv mixed with NK1 (red line). Binding of higher concentrations of 7A2 scFv (dark gray line, 
268 nM) and NK1 (dark blue line, 268 nM) are also shown for comparison. Sensorgrams are shown aligned to 
the start of each 60 s injection. (H and I) Following co-incubation, untagged Fab and His-tagged MET928 were 
exposed to plates coated with HGF/SF (H) or NK1 (I) and bound MET928 detected with anti-5xHis peroxidase 
(Qiagen). Data represent mean and standard deviation of a minimum of three replicates per sample. Fab were 
tested at 5, 50 and 500 nM.
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The domain architectures of MET and its homologue RON differ from those of other receptor tyrosine kinases 
(RTK)46 and are evolutionary and structurally related to the plexins and their semaphorin ligands47. Cryo-EM and 
small angle X-ray scattering (SAXS) analysis of the soluble MET ectodomain42 and several crystal structures30, 37, 44, 45  
have clearly established that the first four extracellular domains of MET (the SEMA, CR and the first two Ig 
domains) can adopt a more compact or a more extended conformation as a result of rotation and translation 
of the CR domain relative to the SEMA domain (Fig. 6A). The present study revealed, unexpectedly, that the 
CR-Ig1-Ig2 domains of MET form a rigid body and this indicates that the first 741 residues of MET contain a 
single hinge, located between the SEMA and CR domains.
The rigid structure of the CR-Ig1-Ig2 fragment has profound implications for the mechanism of MET inhibi-
tion by 107_A07. Crystal structures of soluble fragments of MET in complex with the SPH domain of HGF/SF30, 37  
or InlB44, 45 have shown that the CR domain can adopt two main orientations relative to the SEMA resulting in a 
compact (PDB entry 2UZY) or extended (PDB entries 1SHY and 4K3J) arrangement of the SEMA, CR, Ig1 and 
Ig2 domains (Fig. 6A). The compact architecture prevails in solution as shown by SAXS experiments42 although 
the molecular mechanism for this apparent restriction in hinge flexibility is not known.
One other crystal structure of a MET-antibody complex is available (the Fab fragment of onartuzumab in 
complex with MET567 and the SPH domain of HGF/SF (4K3J)) and shows that onartuzumab binds an area of the 
SEMA domain that overlaps with the secondary binding site of InlB37. Onartuzumab competes for binding with 
both HGF/SF and NK137 and it has been concluded that the binding sites of HGF/SF, InlB and onartuzumab on 
the SEMA domain overlap in full or in part37. In contrast, 107_A07 binds an epitope on the Ig1 domain of MET 
that overlaps with the primary binding site of InlB, yet 107_A07 also competes with HGF/SF and NK1 for MET 
binding.
Structural alignment of the MET-InlB complex and the MET-107_A07 complex indicates that when MET is in 
the compact conformation, the binding sites for InlB on the MET SEMA and 107_A07 on the Ig1 domain are spa-
tially proximate, despite their location on separate domains (Fig. 6B and Fig. S7). While an allosteric mechanism 
cannot be ruled out, steric competition between HGF/SF and 107_A07 when MET is in the compact conforma-
tion would readily explain the observed biochemical competition between HGF/SF and 107_A07. The compact 
conformation of MET predominates in solution42 and occurs in the crystal structure of the InlB-MET741 com-
plex44, 45. Our data further support a role for this conformation in HGF/SF-induced MET signaling.
Our data also demonstrate that the Ig1 residue Cys584 is capable of forming a disulphide bond external to the 
Ig1 domain. A putative disulphide linkage between Cys584 (Ig1 domain) and Cys26 (N-terminal) has been pos-
tulated and discussed previously42, 44, 48 but to our knowledge this is the first time that experimental evidence for 
MET - 107_A07 Fab complex
Data collection
Radiation Source, Beamline ESRF, ID29
Wavelength (Å) 0.91376
Space group P22121
Cell dimensions
 a, b, c (Å) 71.88 82.28 267.30
α, β, γ (°) 90, 90, 90
Resolution (Å) 48.95–2.60 (2.74–2.60)1
Rmeas2 11.1 (88.3)
<I/σ(I)> 11.7 (2.0)
Completeness (%) 99.0 (95.8)
Redundancy 5.5 (5.5)
No. of unique reflections 49,099 (6,685)
Refinement
Resolution (Å) 48.94–2.60
No. of reflections:
 Total 48,940
Rfree set 2,000
Rcryst3/Rfree4 21.5/25.7
Contents of asymmetric unit:
 Protein atoms 10,043
Solvent atoms 88
R.m.s deviations:
Bond lengths (Å) 0.005
Bond angles (°) 0.999
Table 1. Crystallographic data collection and refinement statistics. 1The statistics shown in parentheses are 
for the highest-resolution shell. 2Rmeas = (Σ hkl [N/(N-1)]1/2 Σ i |Ii(hkl)−Imean(hkl)|)/Σ hkl Σ i Ii(hkl), where N is 
redundancy. 3Rcryst = Σ hkl ||Fobs(hkl)|−|Fcalc(hkl)||/Σ hkl |Fobs(hkl)|. 4R free is the same as Rcryst for a random subset 
not included in the refinement of about 4% of total reflection.
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this bond has been observed. Attachment of Cys584 to the N-terminal peptide of MET may have occurred before 
or after proteolysis; whether this disulphide bond exists in intact, full-length MET remains to be determined. The 
possibility is intriguing as such a bond, if it exists, may go some way towards explaining why the compact arrange-
ment of the SEMA, CR, Ig1 and Ig2 domains has been reported to dominate over the extended conformation in 
SAXS experiments42.
The pivotal roles of HGF/SF and MET in cancer progression and metastasis have led to considerable expecta-
tion that agents blocking HGF/SF-MET signaling could have a strong impact in the therapy of metastatic tumors 
Figure 4. Crystal structure of the 107_A07-MET complex. A: Content of the asymmetric unit. The two views 
are related by a 90° rotation along the y axis. Complex molecule 1: MET receptor fragment (519–740) – green; 
MET receptor amino terminal peptide (22–32) – violet; 107_A07 Fab heavy chain – cyan; 107_A07 Fab light 
chain – magenta. Complex molecule 2: MET receptor fragment (519–740) – yellow; MET receptor amino 
terminal peptide (22–32) – orange; 107_A07 Fab heavy chain – salmon pink; 107_A07 Fab light chain – grey. 
The disulfide bridges are shown as sticks. The figure was generated with PYMOL62. B: The view showing the 
position of MET receptor amino-terminal peptide in orange (22–32) relative to MET receptor fragment in 
yellow (519–740). The disulfide bridge between residues Cys26 of the peptide and Cys584 of MET receptor 
fragment is shown in sticks. The zoomed in portion of the figure is showing the final 2Fo-Fc electron density 
map contoured at 1.1 sigma level.
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Figure 5. Structure of the complex between 107_A07 and MET519-740. (A) Ribbon diagram of complex 1 of 
the 107_A07 - MET519-740 structure showing the MET519-740 molecule (green) and the 107_A07 Fab on the 
right (heavy chain cyan, light chain purple). (B,C) Residues involved in contacts between MET519-740 (B) and 
107_A07 Fab (VH domain in cyan, VL domain in purple). The picture highlights the polar and charged nature 
of the extensive VH-MET contacts (see Table S1 for further details). (D) Superposition of the structures of the 
MET fragment containing residues 519–740 from the structure of the 107_A07-MET complex (chain A) and 
the InlB-MET structure (PDB accession 2UZY, chain B). (E and F) Contacts between the CR domain and the 
IG1 domain (E) of MET519-740 and between the bottom of IG1 domain and the top of the IG2 domain (F). 
These two sets of contacts account for the rigid structure of the MET519-740 fragment of MET.
Figure 6. Comparison of the 107_A07 Fab with compact (InlB-bound) and extended (HGF/SFβ-bound) 
structures of the MET ectodomain. (A) The compact (blue) and extended (grey) conformations of extracellular 
MET (amino acids 25–741). The structure of compact MET is from PDB accession 2UZY (chain B), (complex 
of MET with InlB); the structure of MET in extended conformation is from PDB accession code 1SHY (HGF/
SF beta chain in complex with SEMA domain of MET). (B) Superposition of the MET-107_A07 Fab complex 
(shown in green) with MET in compact conformation (2UZY), obtained by superposing the CR domains. The 
MET CRD-Ig1-Ig2 domains are oriented perpendicular to the image. The InternalinB structure is shown in 
red. (C) Superposition with MET in extended conformation (1SHY). The position of Ig1-Ig2 was obtained as 
described in (B). (D) Superposition with MET in extended conformation (4K3J, complex of MET and the Fab 
fragment of onartuzumab). The onartuzumab structure is shown in magenta.
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and led to a major effort in the design, synthesis and development of small molecule inhibitors of the MET kinase49 
as well as blocking antibodies directed against the ligand HGF/SF50, 51 and the MET extracellular region37, 52–56. 
Several anti-MET antibodies progressed to clinical trials, including ABT-70057, LY287535858, ARGX-111 and 
onartuzumab. The development of a number of anti-MET antibodies with antagonistic activity has highlighted 
diverse mechanisms for receptor inhibition. For instance, onartuzumab37 and anti-MET CE-35562154 inhibit 
HGF/SF binding, MET activation and xenograft growth. Anti-MET LMH 8753 does not inhibit ligand binding but 
promotes receptor degradation and anti-MET F46 inhibits ligand binding and promotes receptor degradation59. 
An anti-MET nanobody (a single VH domain) inhibits MET activation and DNA synthesis in myeloma cells60 
and a recent collection of llama anti-MET antibodies highlights multiple mechanisms of receptor inhibition56. 
These multiple pathways of receptor inhibition reflect the complex structural basis of MET signaling30, 44, 45. An 
anti-MET anticalin (PRS-110) with MET antagonistic activity has also been developed61. Interestingly, PRS-110 
binds both to a loop in the SEMA domain in close proximity to the K1 binding site as well as the β-wing of the 
Ig1 of MET suggesting that the PRS-110 and 107_A07 epitopes may be closely related. While crystallographic 
analysis will be required in order to define more accurately the epitopes of a number of other anti-MET antibodies 
under development for therapy, the structures of onartuzumab37 and 107_A07 (this work) in complex with MET 
offer initial insights into mechanisms of MET inhibition. The unusual mechanism of MET inhibition by 107_A07, 
involving biochemical competition for ligand binding despite clear separation of binding footprints, contrasts 
with that of onartuzumab and illuminates the variety of potential mechanisms through which antibody-mediated 
MET inhibition can be achieved.
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